23andMe prevents advertising amongst FDA demands

While 23andMe has created on despite the Foods and Drugs Administration's buy to stop income, the company is now saying it has stopped advertising its products due to the kerfuffle.

According to Reuters, the Google-backed genetic-testing start-up has stopped its TV, music, and on the internet ads for its well-known at-home analyzing offers.

23andMe was published an FDA warning letters two a few several weeks ago. The government company needed the company stop advertising its at-home analyzing offers "immediately" because they needed controlling acceptance and were obviously being promoted in violation of the Foods, Drugs, and Visual Act.

In response, 23andMe launched a brief announcement saying the company's relationship with the FDA is "extremely important to us and we are devoted to absolutely exciting with them to cope with their concerns"

In the meanwhile, however, 23andMe has continuous to provide its at-home analyzing offers as it works to come in complying with the FDA's specifications.

In a brief content 2-3 several weeks ago, the company's designer Angel Wojcicki wrote that the company was trying to convince the FDA of the "quality of our data" and that it was in conversation with the company -- simultaneously somewhat behind in dealing with its specifications.

"This is new place for both 23andMe and the FDA. This makes the controlling process with the FDA important because the perform we are doing with the company will help lay the base for what other companies in this new industry do later on," Wojcicki wrote. "It will also provide important assurance to the group that the process and technological innovation behind the assistance meet the comprehensive specifications needed by those requested with the public's security."